MDM4 and prostate adenocarcinoma: MDM4 was displayed to be of prognostic value for Pheochromocytoma and paraganglioma (PCPG) (HR = 11.516, p = 0.007), PRAD (HR = 3.992, p = 0.022), Thymoma (THYM) (HR = 0.101, p = 0.031), GBMLGG (HR = 1.431, p < 0.001), Brain lower grade glioma (LGG) (HR = 1.511, p < 0.001), and Adrenocortical carcinoma (ACC) (HR = 3.913, p < 0.001).